A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Focal Segmental Glomerulosclerosis (FSGS)
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Nov 2019
Price : $35 *
At a glance
- Drugs CCX 140 (Primary)
- Indications Focal segmental glomerulosclerosis
- Focus Therapeutic Use
- Acronyms LUMINA1
- Sponsors ChemoCentryx
- 05 Nov 2019 According to a ChemoCentryx media release, data from this study will be presented at the American Society of Nephrology (ASN) Kidney Week 2019.
- 19 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 05 Aug 2019 According to a ChemoCentryx media release, the last patient is expected to be randomized in mid-August and top line data anticipated in the first half of 2020.